信：接受双重靶向治疗的两位炎症性肠病患者的 SARS-CoV-2 感染情况-作者答复。
Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
机构信息
Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
出版信息
Aliment Pharmacol Ther. 2021 Mar;53(6):766-767. doi: 10.1111/apt.16287.
Abstract
This article is linked to Al‐Ani et al and Privitera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15779 and https://doi.org/10.1111/apt.16297
摘要
本文与 Al‐Ani 等人的论文和 Privitera 等人的论文相关。要查看这些文章，请访问 https://doi.org/10.1111/apt.15779 和 https://doi.org/10.1111/apt.16297。
相似文献
1
Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.信：接受双重靶向治疗的两位炎症性肠病患者的 SARS-CoV-2 感染情况-作者答复。
Aliment Pharmacol Ther. 2021 Mar;53(6):766-767. doi: 10.1111/apt.16287.
2
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.信：两名接受双重靶向治疗的 IBD 患者感染 SARS-CoV-2。
Aliment Pharmacol Ther. 2021 Mar;53(6):764-765. doi: 10.1111/apt.16271.
3
Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.信件：炎症性肠病护士在疫情期间的关键作用。作者回复。
Aliment Pharmacol Ther. 2020 Aug;52(4):746-747. doi: 10.1111/apt.15954.
4
Prevention of COVID-19 in patients with IBD - Authors' reply.炎症性肠病患者中新型冠状病毒肺炎的预防——作者回复
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):640-641. doi: 10.1016/S2468-1253(20)30156-4.
5
Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'.作者对《炎症性肠病患者中的COVID-19：正确命名的必要性》的回复
J Crohns Colitis. 2021 Jun 22;15(6):1080. doi: 10.1093/ecco-jcc/jjaa240.
6
Inflammatory Bowel Disease and the SARS-CoV-2 Pandemic: More Speed, Less Haste.炎症性肠病与新型冠状病毒肺炎大流行：更快行动，勿急行事。
Gastroenterology. 2021 Jan;160(1):473-474. doi: 10.1053/j.gastro.2020.05.013. Epub 2020 May 8.
7
Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic. Authors' reply.社论：在 COVID-19 大流行背景下，IBD 的患病率及其并发症不断增加。作者回复。
Aliment Pharmacol Ther. 2020 Jun;51(12):1442-1443. doi: 10.1111/apt.15769. Epub 2020 May 14.
8
Reply to the Letter to the Editor: The Incidence and Outcomes of COVID-19 in Patients With IBD: A Rapid Review and Meta-Analysis.致编辑的信的回复：炎症性肠病患者中新冠病毒病的发病率和结局：快速综述与荟萃分析
Inflamm Bowel Dis. 2020 Sep 18;26(10):e127. doi: 10.1093/ibd/izaa172.
9
Editorial: social distancing during the COVID-19 pandemic-IBD patients cannot stay at home forever. Authors' reply.社论：2019冠状病毒病大流行期间的社交距离——炎症性肠病患者不能永远居家。作者回复。
Aliment Pharmacol Ther. 2020 Aug;52(4):719-720. doi: 10.1111/apt.15937.
10
SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.炎症性肠病患者的新型冠状病毒2型疫苗接种——作者回复
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):523-524. doi: 10.1016/S2468-1253(21)00194-1.
本文引用的文献
1
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.信：两名接受双重靶向治疗的 IBD 患者感染 SARS-CoV-2。
Aliment Pharmacol Ther. 2021 Mar;53(6):764-765. doi: 10.1111/apt.16271.
2
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
3
SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn's Disease.新型冠状病毒2型感染与克罗恩病的双重生物治疗
Inflamm Bowel Dis. 2020 Nov 19;26(12):e153-e154. doi: 10.1093/ibd/izaa275.
4
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease.双重靶向治疗：难治性炎症性肠病管理的一种可能选择。
J Crohns Colitis. 2020 Jul 17. doi: 10.1093/ecco-jcc/jjaa149.
5
Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.综述文章：炎症性肠病患者 COVID-19 的预防、诊断和管理。
Aliment Pharmacol Ther. 2020 Jul;52(1):54-72. doi: 10.1111/apt.15779. Epub 2020 May 26.
6
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.两种生物制剂联合治疗难治性克罗恩病的疗效和安全性。
Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719. Epub 2020 Apr 24.
7
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.炎症性肠病的联合生物治疗：来自三级医疗中心的经验。
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.
8
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.对于在接受英夫利昔单抗治疗时未缓解的克罗恩病患者，同时使用那他珠单抗治疗的安全性和耐受性。
Inflamm Bowel Dis. 2007 Jan;13(1):2-11. doi: 10.1002/ibd.20014.
Zotero 插件